ASBP
Aspire Biopharma Holdings, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.26
P/S
630.62
EV/EBITDA
-0.22
DCF Value
$-0.61
FCF Yield
-125.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1.9%
Operating Margin
-312016.9%
Net Margin
-394725.1%
ROE
284.6%
ROA
-1865.7%
ROIC
395.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $4.3K | $-4.7M | $-16.26 |
| FY 2025 | $6.2K | $-24.5M | $-16.38 |
| Q3 2025 | $1.9K | $-1.9M | $-0.01 |
| Q2 2025 | $0.00 | $-2.0M | $-0.01 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.88
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.